Acadian Asset Management
KYMR icon

Acadian Asset Management’s Kymera Therapeutics KYMR Stock Holding History

Acadian Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39K Sell
479
-903
-65% -$71.5K ﹤0.01% 1883
2025
Q4 		$107K Buy
+1,382
New +$93.3K ﹤0.01% 1660
2024
Q4 		– Sell
-2,328
Closed -$110K – 1918
2024
Q3 		$110K Buy
+2,328
New +$103K ﹤0.01% 1562
2021
Q2 		– Sell
-3,004
Closed -$117K – 2113
2021
Q1 		$117K Sell
3,004
-1,975
-40% -$119K ﹤0.01% 1638
2020
Q4 		$309K Buy
+4,979
New +$243K ﹤0.01% 1395

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Acadian Asset Management's KYMR Position: Q1 2026 in Review

Acadian Asset Management reduced its Kymera Therapeutics (KYMR) stake by 65% in Q1 2026, selling an estimated $71.5K and leaving 479 shares worth $39K. The position accounts for ﹤0.01% of the portfolio, ranked #1883.

Acadian Asset Management first reported a position in KYMR in Q4 2020 and has held it in 5 quarters since. The position peaked at $309K in Q4 2020. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Acadian Asset Management held 479 shares of Kymera Therapeutics worth $39K as of Q1 2026.
  • Acadian Asset Management sold 903 Kymera Therapeutics shares in Q1 2026, an estimated $71.5K.
  • Kymera Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1883 holding.
  • Acadian Asset Management first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 5 quarters since.
  • Acadian Asset Management's Kymera Therapeutics position peaked at $309K in Q4 2020.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.